Company: SMNR
Filing Date: 2025-06-11
Form Type: CORRESP
Source: 0001193125-25-139135
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: CORRESP
Chunk 0
---
Denali Capital Acquisition Corp. June 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Franklin Wyman, Angela Connell, Jessica Dickerson, Joe McCann

| Re: | Denali Capital Acquisition Corp. |

Semnur Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-4 Filed April 21, 2025 File No. 333-283019 Ladies and Gentlemen: Denali Capital Acquisition Corp., a Cayman Islands exempted company (the “ Company”), files herewith Amendment No. 2 (“ Amendment No. 2”) to the above-referenced registration statement on Form S-4filed on November 6, 2024, as previously amended by Amendment No. 1 filed on April 21, 2025 (the “ Registration Statement”). Set forth below are the responses of the Company to the comments of the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission (the “ Staff”) with respect to the Registration Statement contained in the Staff’s letter dated May 19, 2025 (the “ Comment Letter”). For ease of reference, each comment contained in the Comment Letter is printed below and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers in Amendment No. 2. All capitalized terms used but not defined in this response letter have the meanings ascribed to such terms in Amendment No. 2. Amendment No. 1 to Registration Statement on Form S-4 Cover Page

| 1. | We note your response to prior comment 6. Specifically, we note your revised disclosure that it is a                                                                                                                                             
 condition of the consummation of the Business Combination that the New Semnur Common Stock and New Semnur Warrants after the Domestication and prior to the Effective Time “remain listed or quoted on the applicable Stock Exchange through the 
 Effective Time, the listing application for the listing of the New Semnur Common Stock and New Semnur Warrants following the Effective Time have been approved by Nasdaq or other Stock Exchange....” Given the recent delisting of Denali’s     
 securities from Nasdaq and the revisions to your definition of “Stock Exchange” to refer to Nasdaq and the OTC Markets, please further revise your disclosure here and throughout the registration statement as appropriate to clarify